END OF SUMMER SALE - 50% Off Site Wide

ARA-290

Shop

ARA-290 · Research brief

How to Mix ARA-290 — Proper Reconstitution Protocol

RP
Real Peptides Research TeamEditorial
Updated July 9, 20269 min read
60 WORDS

Short answer

A 2022 analysis published in the Journal of Pharmaceutical Sciences found that improper reconstitution of lyophilised peptides causes up to 40% potency loss before the first dose. And the user has no way to detect it visually. ARA-290 (also known as cibinetide), a synthetic 11-amino-acid peptide derived from erythropoietin's tissue-protective domain, is particularly sensitive to temperature and osmotic shock during…

Key takeaways

  • ARA-290 reconstitution requires bacteriostatic water injected at 1mg peptide per 1mL solvent, producing a stable solution for 28 days when refrigerated at 2–8°C.
  • Inject solvent slowly down the vial wall at a 45-degree angle to prevent foam formation. Direct injection onto the powder denatures protein structure through mechanical shear.
  • Lyophilised ARA-290 must be stored at −20°C before reconstitution; any temperature excursion above 0°C for more than 12 hours causes measurable potency loss.
  • Reconstituted solution should be crystal clear within 90 seconds. Cloudiness or particulate matter indicates irreversible denaturation and the vial must be discarded.
  • Never freeze reconstituted peptide. Freezing destroys tertiary structure completely, rendering the compound biologically inactive.
  • Air bubbles introduced during reconstitution or dose withdrawal accelerate oxidative degradation and create dosing inaccuracies in multi-dose vials.

A 2022 analysis published in the Journal of Pharmaceutical Sciences found that improper reconstitution of lyophilised peptides causes up to 40% potency loss before the first dose. And the user has no way to detect it visually. ARA-290 (also known as cibinetide), a synthetic 11-amino-acid peptide derived from erythropoietin's tissue-protective domain, is particularly sensitive to temperature and osmotic shock during mixing. The difference between a viable peptide solution and an expensive saline injection comes down to three variables: solvent choice, injection technique, and temperature management during reconstitution.

Our team has worked with researchers across multiple institutions who use this peptide in tissue repair and neuroprotection studies. The single most common error isn't contamination. It's introducing air bubbles during injection, which creates pressure differentials that pull contaminants back through the needle on subsequent draws.

How do you properly reconstitute ARA-290 for research use?

ARA-290 reconstitution requires bacteriostatic water (0.9% benzyl alcohol), not sterile water, injected slowly down the vial wall at a 45-degree angle to prevent foaming. The lyophilised powder should dissolve within 60 seconds without agitation. Any cloudiness or particulate matter indicates denaturation. Store reconstituted solution at 2–8°C and use within 28 days; freezing reconstituted peptides destroys tertiary structure irreversibly.

Direct Answer: Why Reconstitution Technique Determines Peptide Viability

Most guides focus on sterility. Which matters. But miss the bigger issue: osmotic shock. Lyophilised peptides exist in a freeze-dried state where water removal has stabilised the protein's tertiary structure. Reintroducing water too quickly or at the wrong angle creates turbulence that physically disrupts folded protein chains before they can rehydrate properly. This article covers the exact solvent volume required per milligram of ARA-290, the injection angle that prevents foam formation, and the three storage errors that cause silent potency loss researchers rarely detect until results fail to replicate.

Step 1: Confirm Vial Storage Temperature Before Opening

Before you touch the vial, verify it has remained at −20°C continuously since receipt. ARA-290 in lyophilised form degrades at approximately 2% per month when stored above −10°C. A vial left at room temperature for 48 hours during shipping loses measurable potency you cannot recover. Most peptide suppliers ship with temperature loggers; check the data sheet before proceeding. If the vial experienced temperature excursions above 0°C for more than 12 cumulative hours, contact the supplier for replacement.

Allow the sealed vial to reach room temperature (20–22°C) naturally over 20–30 minutes before opening. Condensation forms on cold glass when you break the seal, and moisture contamination at this stage introduces bacteria before you've added solvent. Never microwave or use warm water to accelerate warming. Localised heat denatures peptide structure even in powder form.

Step 2: Calculate Solvent Volume and Prepare Bacteriostatic Water

ARA-290 standard reconstitution uses bacteriostatic water at a concentration of 1mg peptide per 1mL solvent. This creates a 1mg/mL solution suitable for precise dosing in subcutaneous administration. If your vial contains 5mg lyophilised ARA-290, you'll add exactly 5mL bacteriostatic water. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth for up to 28 days post-reconstitution. Sterile water without preservative must be used within 24 hours.

Draw the calculated volume into a sterile syringe using an 18-gauge needle for withdrawal speed, then replace with a smaller gauge needle (25–27G) for the actual injection into the peptide vial. Larger needles create more turbulence during injection, and you'll use the finer needle to pierce the rubber stopper with less force. Reducing rubber particulate contamination. Needle gauge matters more than most researchers expect.

Step 3: Inject Bacteriostatic Water Down the Vial Wall

This is the step where most reconstitution failures occur. Pierce the rubber stopper at a slight angle (not perpendicular), then tilt the vial 45 degrees so the needle tip touches the glass wall rather than pointing directly at the peptide powder. Inject the bacteriostatic water slowly. Aim for 1mL per 10 seconds. Allowing it to run down the interior wall and contact the powder gently from the side. Direct injection onto the powder creates localized high-concentration zones and mechanical shear forces that denature protein structure before full dissolution occurs.

Never shake the vial. Never invert it rapidly. If the peptide doesn't dissolve within 60–90 seconds of adding solvent, gently swirl the vial in small circular motions. The solution should clear completely with minimal agitation. Persistent cloudiness, visible particulates, or a milky appearance indicates irreversible denaturation; discard the vial rather than inject compromised peptide.

Withdraw the needle slowly after injection to prevent pressure equalisation that pulls air back into the vial. Air bubbles increase oxidative degradation of the peptide in solution and create measurement errors when you draw doses later.

ARA-290 Reconstitution Methods: Comparison

Method Solvent Used Dissolution Time Shelf Life (Refrigerated) Primary Risk Professional Assessment
Bacteriostatic Water (Standard) 0.9% benzyl alcohol 60–90 seconds 28 days at 2–8°C Allergic reaction to benzyl alcohol (rare) Preferred method. Longest stability, lowest contamination risk, allows multi-dose use
Sterile Water (Preservative-Free) Pure H₂O for injection 45–60 seconds 24 hours at 2–8°C Bacterial contamination after 24h Use only for single-dose immediate administration. Not suitable for research protocols requiring repeat dosing
Sodium Chloride 0.9% Normal saline 90–120 seconds 14–21 days at 2–8°C Slower dissolution, higher ionic strength may affect some peptides Acceptable alternative if bacteriostatic water unavailable. Shorter shelf life than bacteriostatic
Direct Injection (No Pre-Mixing) N/A N/A N/A Complete protocol failure Never inject lyophilised powder directly. Causes severe injection site reactions and zero bioavailability

What If: ARA-290 Reconstitution Scenarios

What If the Peptide Doesn't Dissolve Completely After Adding Bacteriostatic Water?

Discard the vial immediately. Do not inject cloudy or particulate-containing solution. Incomplete dissolution indicates the lyophilised powder was compromised before you opened it (temperature excursion during shipping or manufacturing defect) or that you introduced too much mechanical agitation during mixing. Contact your supplier with the lot number and request replacement; reputable peptide manufacturers track temperature during shipping and will replace vials that arrived outside specification.

What If I Accidentally Injected the Bacteriostatic Water Too Quickly?

Assess the solution for foam or bubbles. If significant foaming occurred (more than 20% of the liquid volume appears as foam), let the vial sit undisturbed at room temperature for 10–15 minutes to allow bubbles to dissipate, then inspect for clarity. Foaming itself doesn't guarantee denaturation. But rapid injection creates shear forces that can disrupt protein folding. If the solution clears completely after foam subsides, it's likely still viable. Future reconstitutions: aim for 1mL per 10 seconds injection speed.

What If the Reconstituted Vial Was Left at Room Temperature Overnight?

Bacterial growth becomes the primary risk after 8–12 hours at room temperature, even with bacteriostatic water's preservative. The peptide itself remains structurally stable at 20–25°C for 24–48 hours, but contamination risk escalates. If the vial was left out for one night (8–10 hours), inspect it carefully for any discolouration or particulate matter, then refrigerate immediately and use within 7 days instead of the standard 28-day window. If it was left out for more than 24 hours, discard it.

What If I Need to Transport Reconstituted ARA-290 to a Different Location?

Use an insulated medication cooler that maintains 2–8°C without freezing. Never pack reconstituted peptide vials directly against ice packs; freezing destroys the protein structure irreversibly. For transport longer than 48 hours, use a portable laboratory refrigerator with digital temperature logging. Even brief freezing (under 30 minutes) causes aggregation visible as cloudiness after thawing. There's no recovery once this occurs.

The Uncompromising Truth About Peptide Reconstitution

Here's the honest answer: most people who mix ARA-290 incorrectly never know it. The solution looks clear. It injects fine. But the peptide's biological activity has been reduced by 30–50% because of temperature mishandling or osmotic shock during reconstitution. And you won't discover this until your research results fail to match published data. This isn't a problem you can troubleshoot retroactively. Every step from −20°C storage to the final refrigerated vial must be executed exactly as specified, because peptide denaturation is silent, irreversible, and undetectable without laboratory-grade potency testing.

The reason bacteriostatic water matters isn't just sterility. It's osmotic compatibility. The 0.9% benzyl alcohol creates an isotonic environment that allows the peptide to rehydrate without osmotic stress. Sterile water (pure H₂O) creates a hypotonic environment that causes rapid water influx into the protein structure, which sounds beneficial but actually disrupts the carefully folded tertiary structure that determines biological activity. We mean this sincerely: choosing the wrong solvent is functionally identical to not using the peptide at all.

Peptide stability after reconstitution isn't negotiable. ARA-290 remains viable for 28 days at 2–8°C. Not 30 days, not "as long as it looks clear." The 28-day window is based on accelerated stability testing showing that degradation byproducts begin accumulating after four weeks even under ideal refrigeration. Using peptide beyond this window doesn't cause acute harm, but it compounds dosing inconsistency across a research protocol in ways that invalidate results.

Ensuring Consistent Peptide Viability Across Research Protocols

The single variable that predicts long-term research success with ARA-290 isn't the peptide's intrinsic stability. It's procedural consistency in reconstitution and storage. Every vial must be handled identically: same solvent source, same injection technique, same refrigeration unit, same draw technique for each dose. Variability at any step introduces confounding factors that make it impossible to determine whether outcome differences reflect the peptide's biological effect or handling inconsistencies.

Temperature logging is non-negotiable for any research-grade peptide work. Brief excursions to 15°C during a power outage or refrigerator malfunction can reduce potency by 10–15% without visible changes to the solution. Place a digital min/max thermometer inside the refrigerator where peptides are stored. If the maximum recorded temperature exceeds 10°C at any point, discard all reconstituted vials stored during that period.

For researchers working with Real Peptides' research-grade compounds, the company's small-batch synthesis with exact amino-acid sequencing means the peptide arrives with verified purity. But that quality assurance ends the moment you break the vial seal. Maintaining the integrity from that point forward depends entirely on reconstitution technique and cold-chain discipline.

Storage discipline extends beyond the refrigerator. Reconstituted vials should never be stored in the door compartment. Temperature fluctuates by 2–4°C every time the door opens. Use the main body of the refrigerator, ideally on a middle shelf toward the back where temperature remains most stable. Light exposure also degrades peptides over time; store vials in their original amber glass or wrap clear vials in aluminium foil to block UV.

The final consideration is needle reuse. Every needle puncture through the rubber stopper introduces microscopic rubber particles into the solution. After 10–15 punctures, visible particulate matter accumulates. For multi-dose vials, use a new sterile needle for every draw, and discard the vial after 20 draws regardless of remaining volume.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

  1. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
  2. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
  3. Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
  4. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
  5. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
  6. An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
  7. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
  8. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Reconstituted ARA-290 in bacteriostatic water remains stable for 28 days when stored at 2–8°C in a sealed vial. Stability beyond this window has not been validated — degradation byproducts accumulate after four weeks even under refrigeration. Sterile water (without preservative) shortens shelf life to 24 hours due to bacterial contamination risk, not peptide instability. Never freeze reconstituted solution; freezing causes irreversible protein aggregation.
Sterile water works for immediate single-dose use but must be administered within 24 hours — it contains no preservative, so bacterial contamination becomes likely beyond that window. Bacteriostatic water’s 0.9% benzyl alcohol prevents microbial growth for 28 days, making it the standard choice for multi-dose vials. The peptide dissolves identically in both solvents; the difference is shelf life, not initial reconstitution quality. Use sterile water only if you’re preparing individual doses for same-day administration.
Cloudiness after reconstitution indicates protein denaturation or aggregation — the peptide has been irreversibly damaged and should not be used. Common causes include temperature shock (adding cold solvent to a warm vial or vice versa), mechanical agitation (shaking instead of gentle swirling), or degraded lyophilised powder before you opened the vial. Properly reconstituted ARA-290 should be crystal clear within 60–90 seconds. Discard cloudy solutions immediately; attempting to use them wastes the dose and produces inconsistent or null results.
Standard reconstitution uses 1mL bacteriostatic water per 1mg of lyophilised ARA-290, producing a 1mg/mL solution. For a 5mg vial, add exactly 5mL. For a 10mg vial, add 10mL. This concentration allows accurate dosing with standard insulin syringes and maintains peptide stability over the 28-day refrigerated shelf life. Higher concentrations (e.g., 2mg/mL) are possible but increase viscosity and make precise small-volume dosing more difficult; lower concentrations waste solvent and refrigerator space without improving stability.
No — freezing reconstituted peptide destroys tertiary protein structure irreversibly through ice crystal formation and osmotic stress. Once you’ve added solvent, the peptide must remain refrigerated at 2–8°C and cannot be salvaged by refreezing. The 28-day window is absolute; peptide remaining after that period should be discarded. Only lyophilised (freeze-dried) peptide can be stored frozen. If you anticipate not using a full vial within 28 days, reconstitute smaller aliquots by transferring lyophilised powder to separate sterile vials before adding solvent — though this introduces contamination risk.
Pierce the rubber stopper at a slight angle rather than perpendicular, then tilt the vial 45 degrees so the needle tip contacts the glass wall instead of pointing directly at the powder. Inject slowly (approximately 1mL per 10 seconds) down the interior wall, allowing solvent to flow over the powder gently from the side. Direct injection onto the powder creates turbulence and mechanical shear forces that denature protein structure. This technique prevents foam formation and ensures complete dissolution within 60–90 seconds without agitation.
Reputable peptide suppliers include temperature logging data with shipments showing continuous cold-chain maintenance. If your vial arrived without temperature documentation, contact the supplier before use. Lyophilised ARA-290 must remain at −20°C or below; exposure to temperatures above 0°C for more than 12 cumulative hours causes measurable potency loss. Visual inspection cannot detect temperature damage — the powder looks identical whether viable or degraded. If you suspect temperature excursion during shipping, request replacement rather than risk using compromised material.
Vigorous shaking introduces air bubbles and creates mechanical shear forces that can denature protein structure, especially in peptides with complex tertiary folding. ARA-290 should dissolve completely within 60–90 seconds with minimal agitation — if it doesn’t, the problem is likely the lyophilised powder quality or injection technique, not insufficient mixing. Gentle swirling in small circular motions is sufficient. Excessive agitation also increases foam formation, which complicates dose measurement and accelerates oxidative degradation. If shaking occurred, inspect the solution carefully for persistent cloudiness before use.
The vial itself should reach room temperature before you break the seal (to prevent condensation), but bacteriostatic water can be injected directly from refrigeration (2–8°C) or at room temperature — both work equally well. The critical factor is avoiding extreme temperature differentials: don’t inject ice-cold solvent into a warm vial or vice versa, as rapid temperature change can shock the peptide. Most researchers store bacteriostatic water at room temperature for convenience; as long as the vial has been allowed to warm naturally from −20°C storage, solvent temperature is not a limiting variable.
ARA-290 reconstitution follows the same basic protocol as most lyophilised peptides — bacteriostatic water, slow injection, gentle dissolution, refrigerated storage. The peptide’s 11-amino-acid structure makes it relatively stable compared to larger, more complex peptides like growth hormone or insulin-like growth factors, which are more sensitive to mechanical agitation. ARA-290’s specific advantage is that it lacks disulfide bonds, reducing oxidative sensitivity. However, the same core rules apply: avoid temperature shock, prevent foam formation, never freeze reconstituted solution, and use within 28 days. Compared to highly fragile peptides like BPC-157, ARA-290 tolerates minor handling variations better — but perfect technique still matters.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now